Infectious Diseases
NanoViricides Advances Measles Drug Program as Global Outbreaks Rise
NanoViricides, Inc. has begun animal trials for its antiviral candidate NV-387, targeting measles amidst increasing global outbreaks and vaccine challenges, highlighting a critical step towards addressing a significant public health gap.
Soligenix Develops Novel Therapy to Address Antibiotic-Resistant Bacterial Infections
Soligenix's SGX943 represents a potential breakthrough in combating antibiotic-resistant bacteria, offering a novel broad-spectrum therapy that could help address a critical public health challenge.
NanoViricides Highlights Potential Antiviral Solution Amid Changing COVID Booster Recommendations
NanoViricides' President Dr. Anil Diwan comments on the FDA's updated COVID-19 booster policy, emphasizing the need for alternative antiviral treatments and positioning the company's NV-387 drug candidate as a potential solution for respiratory viral infections.
New Research Illuminates Potential Link Between Epstein-Barr Virus and Multiple Sclerosis
Scientific research is uncovering a complex relationship between Epstein-Barr virus exposure and Multiple Sclerosis, highlighting the potential for deeper understanding of disease mechanisms and future treatment strategies.
NanoViricides Advances Broad-Spectrum Antiviral Drug, Eyes Multiple Phase II Trials
NanoViricides is progressing its NV-387 drug candidate across multiple viral infections, with pending Phase II trials for MPox and emerging programs for measles and avian flu, highlighting significant potential in antiviral treatment development.
NanoViricides Advances Promising Antiviral Drug Against Measles and MPox
NanoViricides is developing NV-387, a potential breakthrough treatment for Measles and MPox amid rising global case counts and limited medical interventions. The drug represents a critical advancement in addressing urgent infectious disease challenges.
GeoVax Reveals Promising Dual-Action Vaccine with Potential COVID-19 and Mpox Protection
A novel vaccine candidate, GEO-CM04S1, demonstrates robust immunogenicity against both COVID-19 and Mpox in immunocompromised and healthy populations, offering potential breakthrough in infectious disease prevention.
Rapid Diagnostic Test Developed for Bacterial Meningitis
Researchers at Amsterdam University Medical Center have created a new diagnostic test that can quickly and accurately detect bacterial meningitis by measuring protein levels in cerebrospinal fluid, potentially improving patient outcomes through faster diagnosis.
NanoViricides Advances Measles Drug Development with Promising Broad-Spectrum Antiviral
NanoViricides is developing NV-387, a broad-spectrum antiviral drug candidate targeting measles amid declining vaccination rates. The drug shows potential for addressing infectious disease challenges with its unique therapeutic approach.
Tonix Pharmaceuticals Presents Promising Single-Dose Mpox Vaccine Candidate
Tonix Pharmaceuticals revealed preclinical data for TNX-801, a single-dose mpox vaccine that demonstrates durable protection in animals, including immunocompromised subjects. The vaccine could potentially address global health emergency challenges related to mpox outbreaks.
GeoVax Highlights Mpox Threat After North Carolina Wastewater Detection
Wastewater samples in North Carolina reveal the first state detection of Clade I Mpox, a more virulent strain with higher transmissibility. GeoVax responds by emphasizing the need for expanded vaccine preparedness and domestic manufacturing capabilities.
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data
Tonix Pharmaceuticals presented preclinical data on TNX-801, a single-dose mpox vaccine that demonstrates robust protection across animal models, potentially offering a significant breakthrough in combating global mpox outbreaks.
Soligenix Advances COVID-19 Vaccine Candidate CiVax Amid Ongoing Global Health Threat
Soligenix is developing CiVax, a heat-stable COVID-19 vaccine candidate, in response to persistent global health risks from the virus, with recent preclinical studies showing promising protection against multiple variants.
Fidget Spinner Transforms into Rapid Bacterial Detection Device
Researchers have developed a novel diagnostic tool using a fidget spinner with nanoplasmonic technology to detect bacterial species quickly and accurately. This innovative device could revolutionize point-of-care diagnostics, especially in resource-limited settings.